Ligand Pharmaceuticals
LGND
262 hedge funds and large institutions have $2.47B invested in Ligand Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 80 increasing their positions, 115 reducing their positions, and 34 closing their positions.
48% more capital invested
Capital invested by funds: $1.67B → $2.47B (+$799M)
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
0% more funds holding
Funds holding: 261 → 262 (+1)
5.42% less ownership
Funds ownership: 138.42% → 133% (-5.4%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
30% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 115
72% less call options, than puts
Call options by funds: $39.1M | Put options by funds: $139M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$28.6M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
+$27.3M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$22.1M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$16.8M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$47.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$24.7M |
| 3 |
GCM
Geneva Capital Management
Milwaukee,
Wisconsin
|
-$17.8M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$13.3M |
| 5 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$11.6M |
LGND Hedge Fund Activity: Q2 2020 in Review
262 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2020, worth a combined $2.47B — up 48% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new LGND positions and 34 closed out — a net gain of 5 holders — while 80 added to existing stakes and 115 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $28.6M. The largest seller was Renaissance Technologies, cutting an estimated $47.2M.
- 262 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2020, up from 261 in Q1 2020.
- Funds reported $2.47B of Ligand Pharmaceuticals stock for Q2 2020, up 48% quarter-over-quarter.
- 39 funds opened new Ligand Pharmaceuticals positions in Q2 2020 and 34 closed out, a net change of +5 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2020 was Wasatch Advisors, an estimated $28.6M added.
- The largest Ligand Pharmaceuticals seller in Q2 2020 was Renaissance Technologies, an estimated $47.2M sold.
Based on aggregated 13F filings for Q2 2020.